Tazalok drops, oral solution, 100 ml per bottle.

In stock: 3
$88.00

Ingredients

Active ingredients:

10 mL of the preparation contains a tincture of a mixture of medicinal plant materials (1:10): roots of common meadowsweet (Filipendula vulgaris Moench) – 0.28 g, fresh curly parsley roots (Petroselini radix) – 0.225 g, fresh celery roots (Apiumi radix) – 0.17 g, true bedstraw herb (Galii herba) – 0.135 g, common toadflax herb (Linariae herba) – 0.11 g, marigold flowers (Flores Calendulae) – 0.08 g (extraction solvent – 40% ethanol).

Dosage Form

Oral drops, solution.

Main physical and chemical properties: a clear liquid ranging in color from light brown to brown with a characteristic odor.

Sediment formation may occur during storage.

Pharmacotherapeutic group

Agents used in gynecology. ATC code G02CX.

Pharmacological properties

Pharmacodynamics.

A herbal, non-hormonal preparation with a complex action resulting from the synergistic effects of its components, which exhibit hormone-regulating, antiproliferative, anti-inflammatory, sedative, and general tonic effects. The flavonoids—biologically active substances in Tazalok™—are structurally similar to endogenous estrogen but do not exhibit estrogen-like activity; they are capable of competitively binding to estrogen receptors (androgens) when there is an excess of estrogens (androgens) or their receptors in target organs; they also modulate the activity of enzymes in the aromatase system, thereby inhibiting the conversion of androgens into estrogens. Thus, Tazalok™ exhibits selective antiestrogenic activity, promotes the rhythmic production and normalization of the ratio of gonadotropic hormones, a decrease in prolactin levels and an increase in progesterone levels, corrects the imbalance between estradiol and progesterone, and normalizes the second phase of the menstrual cycle. It has a pronounced effect on the glandular tissue and stromal elements of the mammary glands, ovaries, and uterus; exhibits antiproliferative and anti-inflammatory properties; and prevents the development of dysplastic processes in these tissues. In cases of polycystic ovary syndrome, it helps soften the cyst capsule, reduce its tension through a resorptive effect, and enhance the function of the unaffected part of the ovary. It promotes active resorption of cyst contents and the resolution of painless, firm lumps in the mammary glands, and reduces the mammary glands’ response to the phases of the menstrual cycle. It exhibits antispasmodic properties, as well as analgesic and sedative effects. The biologically active molecules of Tazalok™ have the ability to induce and enhance apoptosis, block the action of growth factors, and inhibit angiogenesis.

Pharmacokinetics.

No pharmacokinetic data are available.

Indications

Menstrual cycle disorders; premenstrual syndrome; algodysmenorrhea; dysmenorrhea; fibrocystic mastopathy; ovarian retention cysts. As part of combination therapy, it is used for endometrial hyperplasia, uterine fibroids, endometriosis, and polycystic ovary syndrome.

Contraindications

Hypersensitivity to any component of the drug.

Interactions with Other Medications and Other Types of Interactions

If you need to take any other medications, inform your doctor.

Special Considerations

Use during pregnancy or while breastfeeding.

Do not use during pregnancy or while breastfeeding.

Effect on reaction time when driving or operating machinery.

No effect.

Directions for Use and Dosage

Dilute 30–40 drops of the medication in ½ glass of boiled water at room temperature. Take 30 minutes before meals 3 times a day. Tazalok™ should be taken for at least 3 months, without interruption during menstruation. The daily dose may be divided into 2 doses. If symptoms recur after discontinuing the medication, treatment should be resumed after consulting a doctor.

Children

This medication should not be used in children, as its efficacy and safety have not been established.

Overdose

Cases of overdose are unlikely. However, cardiovascular system disorders may occur. Treatment: gastric lavage, administration of activated charcoal, and symptomatic therapy.

Side Effects

Skin hypersensitivity reactions and allergic reactions may occasionally occur, including skin rashes, erythema, itching, skin swelling, and infiltrated erythematous patches.

If any adverse reactions occur, discontinue use of the medication and be sure to consult a doctor.

Shelf Life

2.5 years.

Storage Conditions

Store in the original packaging at a temperature not exceeding 25 °C.

Keep out of reach of children.

Packaging

50 mL per bottle, 1 bottle per cardboard box.

100 mL per bottle. 1 bottle per cardboard box. 2 or 3 bottles per cardboard box with a divider.

Dispensing Category

Available without a prescription.

Manufacturer

Dr. Gustav Klein GmbH & Co. KG.

Dr. Gustav Klein GmbH & Co. KG.

Address

Steinenfeld 3, 77736 Zell am Harmersbach, Germany.

Steinenfeld 3, 77736, Zell am Harmersbach, Germany.

Applicant

LLC “UNIVERSAL AGENCY ‘PRO-PHARMA’”.